A new track for understanding the pathogenesis of multiple sclerosis: From the perspective of early developmental deficit caused by the potential 5-HT deficiency in individuals in high-latitude areas

Medical Hypotheses

Volumn 71, Issue 4, 2008, Pages 580-583

  Gong, Xiaoming ^a   Xie, Zuoping ^a   Zuo, Huancong ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN; SEROTONIN; TRYPTOPHAN;

ARTICLE; DEVELOPMENTAL DISORDER; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; LATITUDE; MULTIPLE SCLEROSIS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

ALTITUDE; HUMANS; MELATONIN; MODELS, THEORETICAL; MULTIPLE SCLEROSIS; SEROTONIN;

EID: 50449107187     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.04.026     Document Type: Article

References (41)

1. Trapp B.D., Peterson J., Ransohoff R.M., et al. Axonal transection in the lesions of multiple sclerosis. New Engl J Med 338 (1998) 278-285
2. Ffrench-Constant C. Pathogenesis of multiple sclerosis. Lancet 343 (1994) 271-275
3. Marrie R.A. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol 3 (2004) 709-718
4. Wehr T.A. Melatonin and seasonal rhythms. J Biol Rhythms 12 (1997) 518-527
5. Altun A., and Ugur-Altun B. Melatonin: therapeutic and clinical utilization. Int J Clin Pract 61 (2007) 835-845
6. Constantinescu C.S. Melanin, melatonin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: a rationale for light therapy in multiple sclerosis. Med Hypotheses 45 (1995) 455-458
7. Persinger M.A. A potential multiple resonance mechanism by which weak magnetic fields affect molecules and medical problems: the example of melatonin and experimental "multiple sclerosis". Med Hypotheses 66 (2006) 811-815
8. Sandyk R., and Awerbuch G.I. Relationship of nocturnal melatonin levels to duration and course of multiple sclerosis. Int J Neurosci 75 (1994) 229-237
9. Gluckman P.D., and Hanson M.A. Living with the past: evolution, development, and patterns of disease. Science 305 (2004) 1733-1736
10. Finch C.E., and Crimmins E.M. Inflammatory exposure and historical changes in human life-spans. Science 305 (2004) 1736-1739
11. Hammond S.R., English D.R., and McLeod J.G. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain 123 Pt 5 (2000) 968-974
12. Dean G., McLoughlin H., Brady R., et al. Multiple sclerosis among immigrants in Greater London. Br Med J 1 (1976) 861-864
13. Elian M., and Dean G. Multiple sclerosis among the United Kingdom-born children of immigrants from the West Indies. J Neurol Neurosurg Psychiat 50 (1987) 327-332
14. Alter M., Leibowitz U., and Speer J. Risk of multiple sclerosis related to age at immigration to Israel. Arch Neurol 15 (1966) 234-237
15. Utiger R.D. Melatonin - the hormone of darkness. N Engl J Med 327 (1992) 1377-1379
16. Sugden D. Melatonin biosynthesis in the mammalian pineal gland. Experientia 45 (1989) 922-932
17. Itoh M.T., Ishizuka B., Kuribayashi Y., et al. Melatonin, its precursors, and synthesizing enzyme activities in the human ovary. Mol Hum Reprod 5 (1999) 402-408
18. Partonen T., Partinen M., and Lonnqvist J. Frequencies of seasonal major depressive symptoms at high latitudes. Eur Arch Psychiat Clin Neurosci 243 (1993) 189-192
19. Palinkas L.A., Cravalho M., and Browner D. Seasonal variation of depressive symptoms in Antarctica. Acta Psychiatr Scand 91 (1995) 423-429
20. Karadottir R., and Axelsson J. Melatonin secretion in SAD patients and healthy subjects matched with respect to age and sex. Int J Circumpolar Health 60 (2001) 548-551
21. Lee E.J., Lee M.Y., Chen H.Y., et al. Melatonin attenuates gray and white matter damage in a mouse model of transient focal cerebral ischemia. J Pineal Res 38 (2005) 42-52
22. Sayan H., Ozacmak V.H., Ozen O.A., et al. Beneficial effects of melatonin on reperfusion injury in rat sciatic nerve. J Pineal Res 37 (2004) 143-148
23. Kaptanoglu E., Tuncel M., Palaoglu S., et al. Comparison of the effects of melatonin and methylprednisolone in experimental spinal cord injury. J Neurosurg 93 (2000) 77-84
24. Gul S., Celik S.E., Kalayci M., et al. Dose-dependent neuroprotective effects of melatonin on experimental spinal cord injury in rats. Surg Neurol 64 (2005) 355-361
25. Subramanian P., Mirunalini S., Pandi-Perumal S.R., et al. Melatonin treatment improves the antioxidant status and decreases lipid content in brain and liver of rats. Eur J Pharmacol 571 (2007) 116-119
26. Herrera F., Martin V., Garcia-Santos G., et al. Melatonin prevents glutamate-induced oxytosis in the HT22 mouse hippocampal cell line through an antioxidant effect specifically targeting mitochondria. J Neurochem 100 (2007) 736-746
27. Nelson R.J., and Demas G.E. Role of melatonin in mediating seasonal energetic and immunologic adaptations. Brain Res Bull 44 (1997) 423-430
28. Owens M.J., and Nemeroff C.B. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40 (1994) 288-295
29. Abi-Dargham A., Laruelle M., Aghajanian G.K., et al. The role of serotonin in the pathophysiology and treatment of schizophrenia. J Neuropsychiat Clin Neurosci 9 (1997) 1-17
30. Finkelstein M.M. Effectiveness of selective serotonin reuptake inhibitors. CMAJ 178 (2008) 1185-1186
31. Sharp S.C., and Hellings J.A. Efficacy and safety of selective serotonin reuptake inhibitors in the treatment of depression in children and adolescents: practitioner review. Clin Drug Investigat 26 (2006) 247-255
32. Nobuhara K., Okugawa G., Sugimoto T., et al. Frontal white matter anisotropy and symptom severity of late-life depression: a magnetic resonance diffusion tensor imaging study. J Neurol Neurosurg Psychiat 77 (2006) 120-122
33. Bremner J.D. Structural changes in the brain in depression and relationship to symptom recurrence. CNS Spectrosc 7 (2002) 129-130 p. 135-9
34. Uranova N.A., Vostrikov V.M., Orlovskaya D.D., et al. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res 67 (2004) 269-275
35. Vostrikov V.M., Uranova N.A., Rakhmanova V.I., et al. Lowered oligodendroglial cell density in the prefrontal cortex in schizophrenia. Zh Nevrol Psikhiatr Im S S Korsakova 104 (2004) 47-51
36. Janssen J., Hulshoff Pol H.E., Lampe I.K., et al. Hippocampal changes and white matter lesions in early-onset depression. Biol Psychiat 56 (2004) 825-831
37. Wurtman R.J., and Fernstrom J.D. Control of brain monoamine synthesis by diet and plasma amino acids. Am J Clin Nutr 28 (1975) 638-647
38. Fernstrom J.D. Diet-induced changes in plasma amino acid pattern: effects on the brain uptake of large neutral amino acids, and on brain serotonin synthesis. J Neural Transm Suppl (1979) 55-67
39. Fernstrom J.D. Role of precursor availability in control of monoamine biosynthesis in brain. Physiol Rev 63 (1983) 484-546
40. Markianos M., and Sfagos C. Altered serotonin uptake kinetics in multiple sclerosis. J Neurol 235 (1988) 236-237
41. Sandyk R. Suicidal behavior is attenuated in patients with multiple sclerosis by treatment with electromagnetic fields. Int J Neurosci 87 (1996) 5-15